OncoKB New Data Release - January 29, 2026
Contact OncoKB
Data Release v6.1
January 29, 2026
What's New
We hope everyone is having a great start to the new year! In 2025 OncoKB added fifteen Level 1, eight Level 2, one Level 3 and one Level 4 treatments for unique biomarker-selected indications to the database. A table summarizing these changes can be found here. For more details, please see the “Precision Oncology: 2025 in Review” article, found here.
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 1: Addition of Trastuzumab Derutexcan + Pertuzumab to ERBB2 Amplification in breast cancer based on FDA approval of trastuzumab deruxtecan plus pertuzumab for unresectable or metastatic HER2-positive breast cancer (PMID: 41160818)
Level 1 sensitivity-associated therapeutics currently in OncoKB™ for ERBB2 Amplification in breast cancer: Trastuzumab, Trastuzumab Deruxtecan, Ado-Trastuzumab Emtansine, Margetuximab, Neratinib, Lapatinib, Trastuzumab + Pertuzumab, Trastuzumab + Tucatinib
Gene Curation:
Addition of 9 new genes:
AAMP APCDD1 ASXL3 BACH1 ESCO1 FCGR2B H4C9 HIP1 PAFAH1B2
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
